GABRIELLE BROOKS: Open Payments
NPI 1982201745 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$496 in 28 payments from 8 companies in 2025. Trend: 2023 $262 · 2024 $71 · 2025 $496
Food & beverage: $496
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 12 | $212 |
| Amgen Inc. | 5 | $83 |
| E.R. Squibb & Sons, L.L.C. | 3 | $55 |
| Novartis Pharmaceuticals Corporation | 2 | $46 |
| Novo Nordisk Inc | 2 | $37 |
| AstraZeneca Pharmaceuticals LP | 2 | $33 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
Products named: VYNDAQEL, REPATHA, ELIQUIS, LEQVIO, Wegovy, CAMZYOS, FARXIGA, Kerendia.
Industry payments across AL — which companies pay providers there.
